Eli Lilly and Company (NYSE:LLY) Holdings Raised by Mayflower Financial Advisors LLC

Mayflower Financial Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,135 shares of the company’s stock after purchasing an additional 37 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $2,777,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LLY. Axxcess Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 4.2% during the 3rd quarter. Axxcess Wealth Management LLC now owns 22,780 shares of the company’s stock valued at $20,182,000 after purchasing an additional 916 shares in the last quarter. Alan B Lancz & Associates Inc. lifted its position in Eli Lilly and Company by 1.5% during the 3rd quarter. Alan B Lancz & Associates Inc. now owns 1,730 shares of the company’s stock worth $1,533,000 after acquiring an additional 25 shares during the last quarter. Ted Buchan & Co boosted its holdings in Eli Lilly and Company by 8.6% during the third quarter. Ted Buchan & Co now owns 2,136 shares of the company’s stock valued at $1,892,000 after acquiring an additional 170 shares during the period. Houlihan Financial Resource Group Ltd. bought a new stake in Eli Lilly and Company during the third quarter valued at about $447,000. Finally, Summit Wealth & Retirement Planning Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $262,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 4.3 %

Shares of LLY stock opened at $831.54 on Friday. The company has a market capitalization of $789.40 billion, a P/E ratio of 89.90, a P/E/G ratio of 2.94 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average price of $896.31 and a 200 day moving average price of $867.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. Research analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Bank of America reduced their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,008.41.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.